KIT and acute myeloid leukemia: In addition to the inhibition of the IL-1 receptor pathway, targeting IL1RAP may also inhibit signaling and AML cell growth occurring via the FLT3 and c-KIT pathways with a reduced response to FLT3 ligand, stem cell factor (SCF) and IL-1β (46).